$2.49
+0.05 (+2.05%)
Open$2.54
Previous Close$2.44
Day High$2.61
Day Low$2.46
52W High$16.29
52W Low$5.73
Volume—
Avg Volume361.6K
Market Cap65.99M
P/E Ratio56.50
EPS$0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+480.7% upside
Current
$2.49
$2.49
Target
$14.46
$14.46
$8.98
$14.46 avg
$17.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.60M | 19.31M | 20.88M |
| Net Income | -5,133,777 | -5,587,628 | -4,631,912 |
| Profit Margin | -27.6% | -28.9% | -22.2% |
| EBITDA | -5,451,350 | -5,303,939 | -6,015,367 |
| Free Cash Flow | -4,165,501 | -4,081,500 | -5,685,079 |
| Rev Growth | +22.8% | -8.3% | +12.1% |
| Debt/Equity | 0.56 | 0.49 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |